FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036604857> ?p ?o ?g. }

• W3036604857 endingPage "1261" @default.
• W3036604857 startingPage "1261" @default.
• W3036604857 abstract "Cerebral amyloid angiopathy-related inflammation (CAA-ri), a distinct subtype of cerebral amyloid angiopathy, is characterized by an autoimmune reaction to cerebrovascular β-amyloid deposits. Outcomes and response to immunosuppressive therapy for CAA-ri are poorly understood.To identify clinical, neuroimaging, laboratory, pathologic, or treatment-related associations with outcomes after an episode of CAA-ri.A retrospective cohort study of prospectively identified individuals who presented from July 3, 1998, to November 27, 2017, with a median follow-up of 2.7 years (interquartile range, 1.0-5.5 years). The study included 48 consecutive patients with CAA-ri meeting diagnostic criteria who had at least 1 disease episode and subsequent outcome data. No patients refused or were excluded.Prespecified candidate variables were immunosuppressive therapies, cerebrospinal fluid pleocytosis, magnetic resonance imaging findings of recent infarcts or contrast enhancement, and histopathologic evidence of vessel wall inflammation.Clinical improvement and worsening were defined by persistent changes in signs or symptoms, radiographic improvement by decreased subcortical foci of T2 hyperintensity or T1 enhancement, and radiographic worsening by increased subcortical T2 hyperintensity, T1 enhancement, or infarcts. Disease recurrence was defined as new-onset clinical symptoms associated with new imaging findings.The 48 individuals in the study included 29 women and had a mean (SD) age of 68.9 (9.9) years. Results of presenting magnetic resonance imaging revealed that 10 of 29 patients with CAA-ri (34%) had T1 contrast enhancement, 30 of 32 (94%) had subcortical T2 hyperintensity (22 of 30 [73%] asymmetric), 7 of 32 (22%) had acute or subacute punctate infarcts, and 27 of 31 (87%) had microbleeds. Immunosuppressive treatments after first episodes included corticosteroids (33 [69%]), cyclophosphamide (6 [13%]), and mycophenolate (2 [4%]); 14 patients (29%) received no treatment. Clinical improvement and radiographic improvement were each more likely in individuals treated with an immunosuppressive agent than with no treatment (clinical improvement: 32 of 34 [94%] vs 7 of 14 [50%]; odds ratio, 16.0; 95% CI, 2.72-94.1; radiographic improvement: 24 of 28 [86%] vs 4 of 14 [29%]; odds ratio, 15.0; 95% CI, 3.12-72.1). Recurrence was less likely if CAA-ri was treated with any immunosuppressant agent than not (9 of 34 [26%] vs 10 of 14 [71%]; hazard ratio, 0.19; 95% CI, 0.07-0.48). When controlling for treatment, no variables were associated with outcomes aside from an association between APOE ɛ4 and radiographic improvement (odds ratio, 4.49; 95% CI, 1.11-18.2).These results from a relatively large series of patients with CAA-ri support the effectiveness of immunosuppressive treatment and suggest that early treatment may both improve the initial disease course and reduce the likelihood of recurrence. These results raise the possibility that early blunting of CAA-ri and the autoimmune response may have long-term benefits for the subsequent disease course." @default.
• W3036604857 created "2020-06-25" @default.
• W3036604857 creator A5001829677 @default.
• W3036604857 creator A5005004760 @default.
• W3036604857 creator A5008439763 @default.
• W3036604857 creator A5028305623 @default.
• W3036604857 creator A5050675953 @default.
• W3036604857 creator A5056733365 @default.
• W3036604857 creator A5061174828 @default.
• W3036604857 creator A5061474894 @default.
• W3036604857 creator A5063509357 @default.
• W3036604857 creator A5077205182 @default.
• W3036604857 creator A5083748848 @default.
• W3036604857 date "2020-10-01" @default.
• W3036604857 modified "2023-10-16" @default.
• W3036604857 title "Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation" @default.
• W3036604857 cites W1905168637 @default.
• W3036604857 cites W1924633386 @default.
• W3036604857 cites W1978873309 @default.
• W3036604857 cites W1992953826 @default.
• W3036604857 cites W2000291174 @default.
• W3036604857 cites W2026974795 @default.
• W3036604857 cites W2047266443 @default.
• W3036604857 cites W2073624150 @default.
• W3036604857 cites W2075956197 @default.
• W3036604857 cites W2081316966 @default.
• W3036604857 cites W2091931051 @default.
• W3036604857 cites W2113023788 @default.
• W3036604857 cites W2113705748 @default.
• W3036604857 cites W2122843800 @default.
• W3036604857 cites W2135148614 @default.
• W3036604857 cites W2143060791 @default.
• W3036604857 cites W2146653387 @default.
• W3036604857 cites W2148954037 @default.
• W3036604857 cites W2158742097 @default.
• W3036604857 cites W2158778176 @default.
• W3036604857 cites W2164300497 @default.
• W3036604857 cites W2218666645 @default.
• W3036604857 cites W2321488910 @default.
• W3036604857 cites W2524663621 @default.
• W3036604857 cites W2765577833 @default.
• W3036604857 cites W2783990575 @default.
• W3036604857 cites W2889507322 @default.
• W3036604857 cites W2916439624 @default.
• W3036604857 cites W2976556677 @default.
• W3036604857 cites W2995183059 @default.
• W3036604857 doi "https://doi.org/10.1001/jamaneurol.2020.1782" @default.
• W3036604857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7309570" @default.
• W3036604857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32568365" @default.
• W3036604857 hasPublicationYear "2020" @default.
• W3036604857 type Work @default.
• W3036604857 sameAs 3036604857 @default.
• W3036604857 citedByCount "54" @default.
• W3036604857 countsByYear W30366048572020 @default.
• W3036604857 countsByYear W30366048572021 @default.
• W3036604857 countsByYear W30366048572022 @default.
• W3036604857 countsByYear W30366048572023 @default.
• W3036604857 crossrefType "journal-article" @default.
• W3036604857 hasAuthorship W3036604857A5001829677 @default.
• W3036604857 hasAuthorship W3036604857A5005004760 @default.
• W3036604857 hasAuthorship W3036604857A5008439763 @default.
• W3036604857 hasAuthorship W3036604857A5028305623 @default.
• W3036604857 hasAuthorship W3036604857A5050675953 @default.
• W3036604857 hasAuthorship W3036604857A5056733365 @default.
• W3036604857 hasAuthorship W3036604857A5061174828 @default.
• W3036604857 hasAuthorship W3036604857A5061474894 @default.
• W3036604857 hasAuthorship W3036604857A5063509357 @default.
• W3036604857 hasAuthorship W3036604857A5077205182 @default.
• W3036604857 hasAuthorship W3036604857A5083748848 @default.
• W3036604857 hasBestOaLocation W30366048571 @default.
• W3036604857 hasConcept C119060515 @default.
• W3036604857 hasConcept C126322002 @default.
• W3036604857 hasConcept C126838900 @default.
• W3036604857 hasConcept C142724271 @default.
• W3036604857 hasConcept C143409427 @default.
• W3036604857 hasConcept C146638467 @default.
• W3036604857 hasConcept C167135981 @default.
• W3036604857 hasConcept C2777790613 @default.
• W3036604857 hasConcept C2779134260 @default.
• W3036604857 hasConcept C2779483572 @default.
• W3036604857 hasConcept C2780860705 @default.
• W3036604857 hasConcept C71924100 @default.
• W3036604857 hasConcept C72563966 @default.
• W3036604857 hasConcept C90924648 @default.
• W3036604857 hasConceptScore W3036604857C119060515 @default.
• W3036604857 hasConceptScore W3036604857C126322002 @default.
• W3036604857 hasConceptScore W3036604857C126838900 @default.
• W3036604857 hasConceptScore W3036604857C142724271 @default.
• W3036604857 hasConceptScore W3036604857C143409427 @default.
• W3036604857 hasConceptScore W3036604857C146638467 @default.
• W3036604857 hasConceptScore W3036604857C167135981 @default.
• W3036604857 hasConceptScore W3036604857C2777790613 @default.
• W3036604857 hasConceptScore W3036604857C2779134260 @default.
• W3036604857 hasConceptScore W3036604857C2779483572 @default.
• W3036604857 hasConceptScore W3036604857C2780860705 @default.
• W3036604857 hasConceptScore W3036604857C71924100 @default.
• W3036604857 hasConceptScore W3036604857C72563966 @default.
• W3036604857 hasConceptScore W3036604857C90924648 @default.

• next